{"doi":"10.1002/alz.14132","title":"Predicting continuous amyloid PET values with CSF tau phosphorylation occupancies","abstract":"INTRODUCTION: Cerebrospinal fluid (CSF) tau phosphorylation at multiple sites is associated with cortical amyloid and other pathologic changes in Alzheimer's disease. These relationships can be non-linear. We used an artificial neural network to assess the ability of 10 different CSF tau phosphorylation sites to predict continuous amyloid positron emission tomography (PET) values. METHODS: CSF tau phosphorylation occupancies at 10 sites (including pT181/T181, pT217/T217, pT231/T231 and pT205/T205) were measured by mass spectrometry in 346 individuals (57 cognitively impaired, 289 cognitively unimpaired). We generated synthetic amyloid PET scans using biomarkers and evaluated their performance. RESULTS: Concentration of CSF pT217/T217 had low predictive error (average error: 13%), but also a low predictive range (ceiling 63 Centiloids). CSF pT231/T231 has slightly higher error (average error: 19%) but predicted through a greater range (87 Centiloids). DISCUSSION: Tradeoffs exist in biomarker selection. Some phosphorylation sites offer greater concordance with amyloid PET at lower levels, while others perform better over a greater range. HIGHLIGHTS: Novel pTau isoforms can predict cortical amyloid burden. pT217/T217 accurately predicts cortical amyloid burden in low-amyloid individuals. Traditional CSF biomarkers correspond with higher levels of amyloid.","journal":"Alzheimer s & Dementia","year":2024,"id":442904,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9508,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":255192,"name":"Brian A. Gordon","orcid":"0000-0003-2109-2955","position":1,"is_corresponding":false},{"id":228356,"name":"Nicolas R. Barthélemy","orcid":"0000-0003-4937-2860","position":2,"is_corresponding":false},{"id":228357,"name":"Kanta Horie","orcid":"0000-0001-7736-2614","position":3,"is_corresponding":false},{"id":67986,"name":"Rachel L. Henson","orcid":"0000-0002-0664-0629","position":4,"is_corresponding":false},{"id":850953,"name":"Yingxin He","orcid":"0000-0003-2543-4553","position":5,"is_corresponding":false},{"id":310971,"name":"Shaney Flores","orcid":"0000-0003-2726-8704","position":6,"is_corresponding":false},{"id":301875,"name":"Tammie L.S. Benzinger","orcid":"0000-0002-8114-0552","position":7,"is_corresponding":false},{"id":675635,"name":"John C. Morris","orcid":"0000-0002-2692-4565","position":8,"is_corresponding":false},{"id":228359,"name":"Randall J. Bateman","orcid":"0000-0002-7729-1702","position":9,"is_corresponding":false},{"id":226074,"name":"Beau M. Ances","orcid":"0000-0003-3862-7397","position":10,"is_corresponding":false},{"id":310970,"name":"Suzanne E. Schindler","orcid":"0000-0002-1680-1465","position":11,"is_corresponding":false},{"id":310966,"name":"Julie K. Wisch","orcid":"0000-0003-3624-2784","position":0,"is_corresponding":true}],"reference_count":41,"raw_metadata":null,"created_at":"2026-07-19T02:01:20.107161Z","pmid":"39041391","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}